Ohio State will lead a $12M NIH-funded trial comparing BiPAP and HFNO to improve emergency respiratory care for patients with acute respiratory failure.
The FDA has rejected a biologics license application for apitegromab to treat spinal muscular atrophy, according to manufacturer Scholar Rock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback